Details of the Drug-Related molecule(s) Expression Atlas

General Information of Drug (ID: DMQFD42)

Drug Name
Leriglitazone Drug Info
Synonyms
Hydroxypioglitazone; 146062-44-4; Leriglitazone; Hydroxy Pioglitazone (M-IV); MIN-102; Leriglitazone [USAN]; K824X25AYA; CHEBI:82937; UNII-K824X25AYA; 2,4-Thiazolidinedione, 5-[[4-[2-[5-(1-hydroxyethyl)-2-pyridinyl]ethoxy]phenyl]methyl]-; 5-[[4-[2-[5-(1-hydroxyethyl)pyridin-2-yl]ethoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione; WHO 10868; Hydroxy Pioglitazone-D5 (Major) (M-IV); 2,4-Thiazolidinedione, 5-((4-(2-(5-(1-hydroxyethyl)-2-pyridinyl)ethoxy)phenyl)methyl)-; 5-(4-(2-(5-(1-hydroxyethyl)pyridin-2-yl)ethoxy)benzyl)thiazolidine-2,4-dione; 1-Hydroxypioglitazone; Pioglitazone, hydroxy; LERIGLITAZONE [INN]; Leriglitazone (USAN/INN); CHEMBL1267; SCHEMBL4098326; DTXSID30399914; OXVFDZYQLGRLCD-UHFFFAOYSA-N; BDBM50530214; ZINC01482947; AKOS015856344; DB15021; 5-[[4-[2-[5-(1-Hydroxyethyl)-2-pyridinyl]ethoxy]phenyl]methyl]-2,4-thiazolidinedione; HY-117727; CS-0067030; FT-0643388; D11603; A1-01710; J-008187; Q27156475; 5-(4-{2-[5-(1-hydroxyethyl)pyridin-2-yl]ethoxy}benzyl)-1,3-thiazolidine-2,4-dione; 5-[4-[2-[5-(1-hydroxyethyl)-2-pyridyl]ethoxy]benzyl]-2,4-thiazolidinedione; ALL-AMBO-5-((4-(2-(5-(1-HYDROXYETHYL)PYRIDIN-2-YL)ETHOXY)PHENYL)METHYL)-1,3-THIAZOLE-2,4(3H,5H)-DIONE
Indication
Disease Entry ICD 11 Status REF
Cerebral X-linked adrenoleukodystrophy 5C57.1 Phase 3 [1]
Cross-matching ID
PubChem CID
4147757
TTD Drug ID
DMQFD42

Molecule(s) Related to This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Peroxisome proliferator-activated receptor gamma (PPAR-gamma) TTZMAO3 PPARG_HUMAN Agonist [2]

The Expression Level of Molecule(s) in Normal Tissue of Major ADME-Related Organs

Molecule Molecule Type Gene Name Liver Colon Kidney Small Intestine
Peroxisome proliferator-activated receptor gamma (PPAR-gamma) DTT PPARG 5.576 6.977 5.736 5.758
Molecule Expression Atlas in Normal Tissue of Major ADME-related organs

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

The Studied Disease Cerebral X-linked adrenoleukodystrophy
ICD Disease Classification 5C57.1
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Peroxisome proliferator-activated receptor gamma (PPAR-gamma) DTT PPARG 2.41E-01 -0.06 -0.25
Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1 ClinicalTrials.gov (NCT05819866) A Clinical Study to Assess the Efficacy and Safety of Leriglitazone in Adult Male Subjects With Cerebral Adrenoleukodystrophy. U.S.National Institutes of Health.
2 Clinical pipeline report, company report or official report of Minoryx Therapeutics